Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

Cambridge: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...

New research uncovers new insights into preventing chronic inflammation caused by aging-related zombie-like cells. In humans ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

Here, the authors show that the TG3 enzyme forms complexes with its substrate, gluten, and upon internalization of the whole complex via the B cell receptor, the B cells activate cognate CD4 T cells.